<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20240621222421&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20240621222421&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 22 Jun 2024 02:24:22 +0000</lastbuilddate>
<pubDate>Fri, 21 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Therapeutic potentials of sound waves in cardiovascular medicine: further important evidence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38905142/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 21:ehae253. doi: 10.1093/eurheartj/ehae253. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38905142/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38905142</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae253>10.1093/eurheartj/ehae253</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38905142</guid>
<pubDate>Fri, 21 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Hiroaki Shimokawa</dc:creator>
<dc:date>2024-06-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Therapeutic potentials of sound waves in cardiovascular medicine: further important evidence</dc:title>
<dc:identifier>pmid:38905142</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae253</dc:identifier>
</item>
<item>
<title>Cardiovascular Health, Juneteenth 2024: Are We Thriving Together or Not?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38901532/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 12:S0735-1097(24)07555-7. doi: 10.1016/j.jacc.2024.06.005. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38901532/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38901532</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.005>10.1016/j.jacc.2024.06.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38901532</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer H Mieres</dc:creator>
<dc:creator>Jeffrey T Kuvin</dc:creator>
<dc:creator>Robert O Roswell</dc:creator>
<dc:date>2024-06-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiovascular Health, Juneteenth 2024: Are We Thriving Together or Not?</dc:title>
<dc:identifier>pmid:38901532</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.005</dc:identifier>
</item>
<item>
<title>Excess Cardiovascular Mortality Among Black Americans 2000-2022: A JACC Report Card</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38901531/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 12:S0735-1097(24)07546-6. doi: 10.1016/j.jacc.2024.06.004. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38901531/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38901531</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.004>10.1016/j.jacc.2024.06.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38901531</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Adith S Arun</dc:creator>
<dc:creator>Mitsuaki Sawano</dc:creator>
<dc:creator>Yuan Lu</dc:creator>
<dc:creator>Frederick Warner</dc:creator>
<dc:creator>César Caraballo</dc:creator>
<dc:creator>Rohan Khera</dc:creator>
<dc:creator>Melvin R Echols</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2024-06-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Excess Cardiovascular Mortality Among Black Americans 2000-2022: A JACC Report Card</dc:title>
<dc:identifier>pmid:38901531</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.004</dc:identifier>
</item>
<item>
<title>EnFUSiasm for Healing: Ultrasound Neuromodulation in PAH</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38900858/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 21;135(1):57-59. doi: 10.1161/CIRCRESAHA.124.324791. Epub 2024 Jun 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38900858/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38900858</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11192238/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">PMC11192238</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324791>10.1161/CIRCRESAHA.124.324791</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38900858</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Olga Rafikova</dc:creator>
<dc:creator>Joel James</dc:creator>
<dc:creator>Tatiana V Kudryashova</dc:creator>
<dc:date>2024-06-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>EnFUSiasm for Healing: Ultrasound Neuromodulation in PAH</dc:title>
<dc:identifier>pmid:38900858</dc:identifier>
<dc:identifier>pmc:PMC11192238</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324791</dc:identifier>
</item>
<item>
<title>From Grafts to Genes: Shaping Heart Care With Next-Generation Therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38900857/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 21;135(1):135-137. doi: 10.1161/CIRCRESAHA.124.324573. Epub 2024 Jun 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38900857/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38900857</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324573>10.1161/CIRCRESAHA.124.324573</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38900857</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Monika M Gladka</dc:creator>
<dc:date>2024-06-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>From Grafts to Genes: Shaping Heart Care With Next-Generation Therapies</dc:title>
<dc:identifier>pmid:38900857</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324573</dc:identifier>
</item>
<item>
<title>Congenital Vascular and Lymphatic Diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38900856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>Over the past several centuries, the integration of contemporary medical techniques and innovative technologies, like genetic sequencing, have played a pivotal role in enhancing our comprehension of congenital vascular and lymphatic disorders. Nonetheless, the uncommon and complex characteristics of these disorders, especially considering their formation during the intrauterine stage, present significant obstacles in diagnosis and treatment. Here, we review the intricacies of these congenital...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 21;135(1):159-173. doi: 10.1161/CIRCRESAHA.124.323181. Epub 2024 Jun 20.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Over the past several centuries, the integration of contemporary medical techniques and innovative technologies, like genetic sequencing, have played a pivotal role in enhancing our comprehension of congenital vascular and lymphatic disorders. Nonetheless, the uncommon and complex characteristics of these disorders, especially considering their formation during the intrauterine stage, present significant obstacles in diagnosis and treatment. Here, we review the intricacies of these congenital abnormalities, offering an in-depth examination of key diagnostic approaches, genetic factors, and therapeutic methods.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38900856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38900856</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11192239/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">PMC11192239</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323181>10.1161/CIRCRESAHA.124.323181</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38900856</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Roy Jung</dc:creator>
<dc:creator>Chinmay M Trivedi</dc:creator>
<dc:date>2024-06-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Congenital Vascular and Lymphatic Diseases</dc:title>
<dc:identifier>pmid:38900856</dc:identifier>
<dc:identifier>pmc:PMC11192239</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323181</dc:identifier>
</item>
<item>
<title>Emerging Roles and Therapeutic Applications of Arachidonic Acid Pathways in Cardiometabolic Diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38900855/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>Cardiometabolic disease has become a major health burden worldwide, with sharply increasing prevalence but highly limited therapeutic interventions. Emerging evidence has revealed that arachidonic acid derivatives and pathway factors link metabolic disorders to cardiovascular risks and intimately participate in the progression and severity of cardiometabolic diseases. In this review, we systemically summarized and updated the biological functions of arachidonic acid pathways in cardiometabolic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 21;135(1):222-260. doi: 10.1161/CIRCRESAHA.124.324383. Epub 2024 Jun 20.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiometabolic disease has become a major health burden worldwide, with sharply increasing prevalence but highly limited therapeutic interventions. Emerging evidence has revealed that arachidonic acid derivatives and pathway factors link metabolic disorders to cardiovascular risks and intimately participate in the progression and severity of cardiometabolic diseases. In this review, we systemically summarized and updated the biological functions of arachidonic acid pathways in cardiometabolic diseases, mainly focusing on heart failure, hypertension, atherosclerosis, nonalcoholic fatty liver disease, obesity, and diabetes. We further discussed the cellular and molecular mechanisms of arachidonic acid pathway-mediated regulation of cardiometabolic diseases and highlighted the emerging clinical advances to improve these pathological conditions by targeting arachidonic acid metabolites and pathway factors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38900855/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38900855</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324383>10.1161/CIRCRESAHA.124.324383</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38900855</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Yufeng Hu</dc:creator>
<dc:creator>Wei Li</dc:creator>
<dc:creator>Xu Cheng</dc:creator>
<dc:creator>Hailong Yang</dc:creator>
<dc:creator>Zhi-Gang She</dc:creator>
<dc:creator>Jingjing Cai</dc:creator>
<dc:creator>Hongliang Li</dc:creator>
<dc:creator>Xiao-Jing Zhang</dc:creator>
<dc:date>2024-06-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Emerging Roles and Therapeutic Applications of Arachidonic Acid Pathways in Cardiometabolic Diseases</dc:title>
<dc:identifier>pmid:38900855</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324383</dc:identifier>
</item>
<item>
<title>The Discovery of Extracellular Vesicles and Their Emergence as a Next-Generation Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38900854/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>From their humble discovery as cellular debris to cementing their natural capacity to transfer functional molecules between cells, the long-winded journey of extracellular vesicles (EVs) now stands at the precipice as a next-generation cell-free therapeutic tool to revolutionize modern-day medicine. This perspective provides a snapshot of the discovery of EVs to their emergence as a vibrant field of biology and the renaissance they usher in the field of biomedical sciences as therapeutic agents...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 21;135(1):198-221. doi: 10.1161/CIRCRESAHA.123.323054. Epub 2024 Jun 20.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">From their humble discovery as cellular debris to cementing their natural capacity to transfer functional molecules between cells, the long-winded journey of extracellular vesicles (EVs) now stands at the precipice as a next-generation cell-free therapeutic tool to revolutionize modern-day medicine. This perspective provides a snapshot of the discovery of EVs to their emergence as a vibrant field of biology and the renaissance they usher in the field of biomedical sciences as therapeutic agents for cardiovascular pathologies. Rapid development of bioengineered EVs is providing innovative opportunities to overcome biological challenges of natural EVs such as potency, cargo loading and enhanced secretion, targeting and circulation half-life, localized and sustained delivery strategies, approaches to enhance systemic circulation, uptake and lysosomal escape, and logistical hurdles encompassing scalability, cost, and time. A multidisciplinary collaboration beyond the field of biology now extends to chemistry, physics, biomaterials, and nanotechnology, allowing rapid development of designer therapeutic EVs that are now entering late-stage human clinical trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38900854/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38900854</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323054>10.1161/CIRCRESAHA.123.323054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38900854</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Alin Rai</dc:creator>
<dc:creator>Bethany Claridge</dc:creator>
<dc:creator>Jonathan Lozano</dc:creator>
<dc:creator>David W Greening</dc:creator>
<dc:date>2024-06-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>The Discovery of Extracellular Vesicles and Their Emergence as a Next-Generation Therapy</dc:title>
<dc:identifier>pmid:38900854</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323054</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38900853/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 21;135(1):3-5. doi: 10.1161/RES.0000000000000678. Epub 2024 Jun 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38900853/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38900853</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000678>10.1161/RES.0000000000000678</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38900853</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38900853</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000678</dc:identifier>
</item>
<item>
<title>G Protein-Coupled Receptors: A Century of Research and Discovery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38900852/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>GPCRs (G protein-coupled receptors), also known as 7 transmembrane domain receptors, are the largest receptor family in the human genome, with ≈800 members. GPCRs regulate nearly every aspect of human physiology and disease, thus serving as important drug targets in cardiovascular disease. Sharing a conserved structure comprised of 7 transmembrane α-helices, GPCRs couple to heterotrimeric G-proteins, GPCR kinases, and β-arrestins, promoting downstream signaling through second messengers and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 21;135(1):174-197. doi: 10.1161/CIRCRESAHA.124.323067. Epub 2024 Jun 20.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">GPCRs (G protein-coupled receptors), also known as 7 transmembrane domain receptors, are the largest receptor family in the human genome, with ≈800 members. GPCRs regulate nearly every aspect of human physiology and disease, thus serving as important drug targets in cardiovascular disease. Sharing a conserved structure comprised of 7 transmembrane α-helices, GPCRs couple to heterotrimeric G-proteins, GPCR kinases, and β-arrestins, promoting downstream signaling through second messengers and other intracellular signaling pathways. GPCR drug development has led to important cardiovascular therapies, such as antagonists of β-adrenergic and angiotensin II receptors for heart failure and hypertension, and agonists of the glucagon-like peptide-1 receptor for reducing adverse cardiovascular events and other emerging indications. There continues to be a major interest in GPCR drug development in cardiovascular and cardiometabolic disease, driven by advances in GPCR mechanistic studies and structure-based drug design. This review recounts the rich history of GPCR research, including the current state of clinically used GPCR drugs, and highlights newly discovered aspects of GPCR biology and promising directions for future investigation. As additional mechanisms for regulating GPCR signaling are uncovered, new strategies for targeting these ubiquitous receptors hold tremendous promise for the field of cardiovascular medicine.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38900852/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38900852</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11192237/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">PMC11192237</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323067>10.1161/CIRCRESAHA.124.323067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38900852</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Samuel Liu</dc:creator>
<dc:creator>Preston J Anderson</dc:creator>
<dc:creator>Sudarshan Rajagopal</dc:creator>
<dc:creator>Robert J Lefkowitz</dc:creator>
<dc:creator>Howard A Rockman</dc:creator>
<dc:date>2024-06-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>G Protein-Coupled Receptors: A Century of Research and Discovery</dc:title>
<dc:identifier>pmid:38900852</dc:identifier>
<dc:identifier>pmc:PMC11192237</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323067</dc:identifier>
</item>
<item>
<title>Editors and Editorial Board</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38900851/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 21;135(1):1. doi: 10.1161/RES.0000000000000679. Epub 2024 Jun 20.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38900851/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38900851</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000679>10.1161/RES.0000000000000679</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38900851</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Editors and Editorial Board</dc:title>
<dc:identifier>pmid:38900851</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000679</dc:identifier>
</item>
<item>
<title>&lt;em>;CYP2C19&lt;/em>; Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38899464/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>There is significant variability in the efficacy and safety of oral P2Y12 inhibitors, which are used to prevent ischemic outcomes in common diseases such as coronary and peripheral arterial disease and stroke. Clopidogrel, a prodrug, is the most used oral P2Y12 inhibitor and is activated primarily after being metabolized by a highly polymorphic hepatic cytochrome CYP2C219 enzyme. Loss-of-function genetic variants in CYP2C219 are common, can result in decreased active metabolite levels and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 20. doi: 10.1161/CIR.0000000000001257. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There is significant variability in the efficacy and safety of oral P2Y12 inhibitors, which are used to prevent ischemic outcomes in common diseases such as coronary and peripheral arterial disease and stroke. Clopidogrel, a prodrug, is the most used oral P2Y12 inhibitor and is activated primarily after being metabolized by a highly polymorphic hepatic cytochrome CYP2C219 enzyme. Loss-of-function genetic variants in <i>CYP2C219</i> are common, can result in decreased active metabolite levels and increased on-treatment platelet aggregation, and are associated with increased ischemic events on clopidogrel therapy. Such patients can be identified by <i>CYP2C19</i> genetic testing and can be treated with alternative therapy. Conversely, universal use of potent oral P2Y12 inhibitors such as ticagrelor or prasugrel, which are not dependent on CYP2C19 for activation, has been recommended but can result in increased bleeding. Recent clinical trials and meta-analyses have demonstrated that a precision medicine approach in which loss-of-function carriers are prescribed ticagrelor or prasugrel and noncarriers are prescribed clopidogrel results in reducing ischemic events without increasing bleeding risk. The evidence to date supports <i>CYP2C19</i> genetic testing before oral P2Y12 inhibitors are prescribed in patients with acute coronary syndromes or percutaneous coronary intervention. Clinical implementation of such genetic testing will depend on among multiple factors: rapid availability of results or adoption of the concept of performing preemptive genetic testing, provision of easy-to-understand results with therapeutic recommendations, and seamless integration in the electronic health record.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38899464/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38899464</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001257>10.1161/CIR.0000000000001257</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38899464</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Naveen L Pereira</dc:creator>
<dc:creator>Sharon Cresci</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Wayne Batchelor</dc:creator>
<dc:creator>Quinn Capers</dc:creator>
<dc:creator>Larisa H Cavallari</dc:creator>
<dc:creator>Dana Leifer</dc:creator>
<dc:creator>Jasmine A Luzum</dc:creator>
<dc:creator>Dan M Roden</dc:creator>
<dc:creator>Konstantinos Stellos</dc:creator>
<dc:creator>Stephanie L Turrise</dc:creator>
<dc:creator>Sony Tuteja</dc:creator>
<dc:creator>American Heart Association Professional/Public Education and Publications Committee of the Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease; and Stroke Council</dc:creator>
<dc:date>2024-06-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>&lt;em>;CYP2C19&lt;/em>; Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38899464</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001257</dc:identifier>
</item>
<item>
<title>Fibroblast Smad7 Induction Protects the Remodeling Pressure-Overloaded Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38899461/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The antifibrotic effects of Smad7 in the pressure-overloaded heart protect from dysfunction and involve not only reduction in collagen deposition but also suppression of MMP2-mediated matrix denaturation and paracrine effects that suppress macrophage activation through inhibition of matricellular proteins.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 20. doi: 10.1161/CIRCRESAHA.123.323360. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac fibroblast activation contributes to adverse remodeling, fibrosis, and dysfunction in the pressure-overloaded heart. Although early fibroblast TGF-β (transforming growth factor-β)/Smad (small mother against decapentaplegic)-3 activation protects the pressure-overloaded heart by preserving the matrix, sustained TGF-β activation is deleterious, accentuating fibrosis and dysfunction. Thus, endogenous mechanisms that negatively regulate the TGF-β response in fibroblasts may be required to protect from progressive fibrosis and adverse remodeling. We hypothesized that Smad7, an inhibitory Smad that restrains TGF-β signaling, may be induced in the pressure-overloaded myocardium and may regulate fibrosis, remodeling, and dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The effects of myofibroblast-specific Smad7 loss were studied in a mouse model of transverse aortic constriction, using echocardiography, histological analysis, and molecular analysis. Proteomic studies in S7KO (Smad7 knockout) and overexpressing cells were used to identify fibroblast-derived mediators modulated by Smad7. In vitro experiments using cultured cardiac fibroblasts, fibroblasts populating collagen lattices, and isolated macrophages were used to dissect the molecular signals responsible for the effects of Smad7.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Following pressure overload, Smad7 was upregulated in cardiac myofibroblasts. TGF-β and angiotensin II stimulated fibroblast Smad7 upregulation via Smad3, whereas GDF15 (growth differentiation factor 15) induced Smad7 through GFRAL (glial cell line-derived neurotrophic factor family receptor α-like). MFS7KO (myofibroblast-specific S7KO) mice had increased mortality, accentuated systolic dysfunction and dilative remodeling, and accelerated diastolic dysfunction in response to transverse aortic constriction. Increased dysfunction in MFS7KO hearts was associated with accentuated fibrosis and increased MMP (matrix metalloproteinase)-2 activity and collagen denaturation. Secretomic analysis showed that Smad7 loss accentuates secretion of structural collagens and matricellular proteins and markedly increases MMP2 secretion. In contrast, Smad7 overexpression reduced MMP2 levels. In fibroblasts populating collagen lattices, the effects of Smad7 on fibroblast-induced collagen denaturation and pad contraction were partly mediated via MMP2 downregulation. Surprisingly, MFS7KO mice also exhibited significant macrophage expansion caused by paracrine actions of Smad7 null fibroblasts that stimulate macrophage proliferation and fibrogenic activation. Macrophage activation involved the combined effects of the fibroblast-derived matricellular proteins CD5L (CD5 antigen-like), SPARC (secreted protein acidic and rich in cysteine), CTGF (connective tissue growth factor), ECM1 (extracellular matrix protein 1), and TGFBI (TGFB induced).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The antifibrotic effects of Smad7 in the pressure-overloaded heart protect from dysfunction and involve not only reduction in collagen deposition but also suppression of MMP2-mediated matrix denaturation and paracrine effects that suppress macrophage activation through inhibition of matricellular proteins.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38899461/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38899461</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323360>10.1161/CIRCRESAHA.123.323360</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38899461</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Claudio Humeres</dc:creator>
<dc:creator>Arti V Shinde</dc:creator>
<dc:creator>Izabela Tuleta</dc:creator>
<dc:creator>Silvia C Hernandez</dc:creator>
<dc:creator>Anis Hanna</dc:creator>
<dc:creator>Shuaibo Huang</dc:creator>
<dc:creator>Harikrishnan Venugopal</dc:creator>
<dc:creator>Jennifer T Aguilan</dc:creator>
<dc:creator>Simon J Conway</dc:creator>
<dc:creator>Simone Sidoli</dc:creator>
<dc:creator>Nikolaos G Frangogiannis</dc:creator>
<dc:date>2024-06-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Fibroblast Smad7 Induction Protects the Remodeling Pressure-Overloaded Heart</dc:title>
<dc:identifier>pmid:38899461</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323360</dc:identifier>
</item>
<item>
<title>Cardiac shockwave therapy in addition to coronary bypass surgery improves myocardial function in ischaemic heart failure: the CAST-HF trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38898573/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In conclusion, the CAST-HF trial indicates that direct cardiac SWT, in addition to coronary bypass surgery improves LVEF and physical capacity in patients with ischaemic heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 20:ehae341. doi: 10.1093/eurheartj/ehae341. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In chronic ischaemic heart failure, revascularisation strategies control symptoms but are less effective in improving left ventricular ejection fraction (LVEF). The aim of this trial is to investigate the safety of cardiac shockwave therapy (SWT) as a novel treatment option and its efficacy in increasing cardiac function by inducing angiogenesis and regeneration in hibernating myocardium.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this single-blind, parallel-group, sham-controlled trial (cardiac shockwave therapy for ischemic heart failure, CAST-HF; NCT03859466) patients with LVEF ≤40% requiring surgical revascularisation were enrolled. Patients were randomly assigned to undergo direct cardiac SWT or sham treatment in addition to coronary bypass surgery. The primary efficacy endpoint was the improvement in LVEF measured by cardiac magnetic resonance imaging from baseline to 360 days.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 63 patients were randomized, out of which 30 patients of the SWT group and 28 patients of the Sham group attained 1-year follow-up of the primary endpoint. Greater improvement in LVEF was observed in the SWT group (Δ from baseline to 360 days: SWT 11.3%, SD 8.8; Sham 6.3%, SD 7.4, P = .0146). Secondary endpoints included the 6-minute walking test, where patients randomized in the SWT group showed a greater Δ from baseline to 360 days (127.5 m, SD 110.6) than patients in the Sham group (43.6 m, SD 172.1) (P = .028) and Minnesota Living with Heart Failure Questionnaire score on day 360, which was 11.0 points (SD 19.1) for the SWT group and 17.3 points (SD 15.1) for the Sham group (P = .15). Two patients in the treatment group died for non-device-related reasons.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In conclusion, the CAST-HF trial indicates that direct cardiac SWT, in addition to coronary bypass surgery improves LVEF and physical capacity in patients with ischaemic heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38898573/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38898573</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae341>10.1093/eurheartj/ehae341</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38898573</guid>
<pubDate>Thu, 20 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Johannes Holfeld</dc:creator>
<dc:creator>Felix Nägele</dc:creator>
<dc:creator>Leo Pölzl</dc:creator>
<dc:creator>Clemens Engler</dc:creator>
<dc:creator>Michael Graber</dc:creator>
<dc:creator>Jakob Hirsch</dc:creator>
<dc:creator>Sophia Schmidt</dc:creator>
<dc:creator>Agnes Mayr</dc:creator>
<dc:creator>Felix Troger</dc:creator>
<dc:creator>Mathias Pamminger</dc:creator>
<dc:creator>Markus Theurl</dc:creator>
<dc:creator>Michael Schreinlechner</dc:creator>
<dc:creator>Nikolay Sappler</dc:creator>
<dc:creator>Elfriede Ruttmann-Ulmer</dc:creator>
<dc:creator>Wolfgang Schaden</dc:creator>
<dc:creator>John P Cooke</dc:creator>
<dc:creator>Hanno Ulmer</dc:creator>
<dc:creator>Axel Bauer</dc:creator>
<dc:creator>Can Gollmann-Tepeköylü</dc:creator>
<dc:creator>Michael Grimm</dc:creator>
<dc:date>2024-06-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac shockwave therapy in addition to coronary bypass surgery improves myocardial function in ischaemic heart failure: the CAST-HF trial</dc:title>
<dc:identifier>pmid:38898573</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae341</dc:identifier>
</item>
<item>
<title>Proximity-based labelling for proteomic mapping</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38898320/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 19. doi: 10.1038/s41569-024-01054-6. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38898320/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38898320</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01054-6>10.1038/s41569-024-01054-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38898320</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Zuzanna Jablonska</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Proximity-based labelling for proteomic mapping</dc:title>
<dc:identifier>pmid:38898320</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01054-6</dc:identifier>
</item>
<item>
<title>Suture-to-scan: ultrasonography-guided induction of heart injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38898319/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 19. doi: 10.1038/s41569-024-01055-5. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38898319/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38898319</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01055-5>10.1038/s41569-024-01055-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38898319</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Bronwyn Berkeley</dc:creator>
<dc:creator>Adrian Thomson</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Suture-to-scan: ultrasonography-guided induction of heart injury</dc:title>
<dc:identifier>pmid:38898319</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01055-5</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897683/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2714. doi: 10.1016/j.jacc.2024.05.010.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897683/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38897683</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.010>10.1016/j.jacc.2024.05.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897683</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:38897683</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.010</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897682/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2714. doi: 10.1016/j.jacc.2024.05.033.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897682/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38897682</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.033>10.1016/j.jacc.2024.05.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897682</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:38897682</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.033</dc:identifier>
</item>
<item>
<title>Early Renal Dysfunction in Middle-Aged Adults Predicts Fatal and Nonfatal Cardiovascular Events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897681/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2711-2713. doi: 10.1016/j.jacc.2024.04.029.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897681/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38897681</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.029>10.1016/j.jacc.2024.04.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897681</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Yap-Hang Chan</dc:creator>
<dc:creator>Jie V Zhao</dc:creator>
<dc:creator>Shiu-Lun Au Yeung</dc:creator>
<dc:creator>Yuen-Kwun Wong</dc:creator>
<dc:creator>Ka-Wing Au</dc:creator>
<dc:creator>Aimin Xu</dc:creator>
<dc:creator>Tai-Hing Lam</dc:creator>
<dc:creator>Bernard M Y Cheung</dc:creator>
<dc:creator>Karen Siu-Ling Lam</dc:creator>
<dc:creator>Hung-Fat Tse</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Early Renal Dysfunction in Middle-Aged Adults Predicts Fatal and Nonfatal Cardiovascular Events</dc:title>
<dc:identifier>pmid:38897681</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.029</dc:identifier>
</item>
<item>
<title>A Time for Reflection: 10 Years With JACC</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897680/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2708-2710. doi: 10.1016/j.jacc.2024.05.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897680/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38897680</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.020>10.1016/j.jacc.2024.05.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897680</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Time for Reflection: 10 Years With JACC</dc:title>
<dc:identifier>pmid:38897680</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.020</dc:identifier>
</item>
<item>
<title>Addressing the Global Burden of Cardiovascular Disease in Women: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897679/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240621222421&amp;v=2.18.0.post9+e462414
      <description>Cardiovascular diseases (CVDs) are responsible for approximately 35% of all deaths in women. In 2019, the global age-standardized CVD prevalence and mortality of women were 6,403 per 100,000 and 204 per 100,000, respectively. Although the age- and population-adjusted prevalence has decreased globally, opposite trends are evident in regions of socioeconomic deprivation. Cardiovascular health and outcomes are influenced by regional socioeconomic, environmental, and community factors, in addition...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2690-2707. doi: 10.1016/j.jacc.2024.04.028.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular diseases (CVDs) are responsible for approximately 35% of all deaths in women. In 2019, the global age-standardized CVD prevalence and mortality of women were 6,403 per 100,000 and 204 per 100,000, respectively. Although the age- and population-adjusted prevalence has decreased globally, opposite trends are evident in regions of socioeconomic deprivation. Cardiovascular health and outcomes are influenced by regional socioeconomic, environmental, and community factors, in addition to health care system and individual factors. Cardiovascular care in women is commonly plagued by delayed diagnoses, undertreatment, and knowledge gaps, particularly in women-specific or women-predominant conditions. In this paper, we describe the global epidemiology of CVD and highlight multilevel determinants of cardiometabolic health. We review knowledge and health care gaps that serve as barriers to improving CVD outcomes in women. Finally, we present national, community, health care system, and research strategies to comprehensively address cardiometabolic risk and improve outcomes in women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897679/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240621222421&v=2.18.0.post9+e462414">38897679</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.028>10.1016/j.jacc.2024.04.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897679</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Dominique Vervoort</dc:creator>
<dc:creator>Ruoting Wang</dc:creator>
<dc:creator>Guowei Li</dc:creator>
<dc:creator>Lynaea Filbey</dc:creator>
<dc:creator>Omosivie Maduka</dc:creator>
<dc:creator>LaPrincess C Brewer</dc:creator>
<dc:creator>Mamas A Mamas</dc:creator>
<dc:creator>Maria Cecilia Bahit</dc:creator>
<dc:creator>Sofia B Ahmed</dc:creator>
<dc:creator>Harriette G C Van Spall</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Addressing the Global Burden of Cardiovascular Disease in Women: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38897679</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.028</dc:identifier>
</item>





























</channel>
</rss>